PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc. ® (“Mirati”). With the completion of ...

SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced new clinical and preclinical research will be presented at ...

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along ...

SAN DIEGO, June 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) ® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44 th Annual Global ...

SAN DIEGO, Sept. 19, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL–1 study ...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati ...

SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a ...

Bristol Myers Squibb Co. said Sunday it will buy Mirati Therapeutics Inc. in a deal valued at up to $5.8 billion. The pharmaceutical giant announced it will pay $58 a share for Mirati, for a total ...

11 analysts have expressed a variety of opinions on Mirati Therapeutics (NASDAQ:MRTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a ...

Bristol Myers Squibb & Co (NYSE:BMY) has agreed to acquire Mirati Therapeutics Inc (NASDAQ:MRTX) for $58.00 per share in cash, for a total equity value of $4.8 billion. Mirati stockholders will also ...

China's status at the summit of the Nature Index remains unrivalled as the gap between it and the United States grows. The key question is where Chinese research will go next. As the nation seeks ...